Fauvre, A., Ursino, C., Garambois, V., Culerier, E., Milazzo, L., Vezzio-Vié, N., . . . Faget, J. (2025). Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice. Journal for immunotherapy of cancer, 13(3), e010791. https://doi.org/10.1136/jitc-2024-010791
Citace podle Chicago (17th ed.)Fauvre, Alexandra, et al. "Oxaliplatin, ATR Inhibitor and Anti-PD-1 Antibody Combination Therapy Controls Colon Carcinoma Growth, Induces Local and Systemic Changes in the Immune Compartment, and Protects Against Tumor Rechallenge in Mice." Journal for Immunotherapy of Cancer 13, no. 3 (2025): e010791. https://doi.org/10.1136/jitc-2024-010791.
Citace podle MLA (9th ed.)Fauvre, Alexandra, et al. "Oxaliplatin, ATR Inhibitor and Anti-PD-1 Antibody Combination Therapy Controls Colon Carcinoma Growth, Induces Local and Systemic Changes in the Immune Compartment, and Protects Against Tumor Rechallenge in Mice." Journal for Immunotherapy of Cancer, vol. 13, no. 3, 2025, p. e010791, https://doi.org/10.1136/jitc-2024-010791.